Cardio-Oncology: Principles, Prevention and Management is a clinical volume that focuses on the basic science of cardio-oncology, addresses cardiotoxicity as a consequence of cancer therapy, and discusses prevention, diagnosis and management of cardiovascular disease in patients with cancer. This comprehensive volume presents unique perspectives ranging from basic science to clinical medicine in the field of cardio-oncology. It would be a valuable resource for cardiologists, oncologists, internists, and pediatricians caring for patients with cancer who have cardiovascular risk factors, as well as for cardio-oncology researchers. - Covers basic science of cardio-oncology to provide readers with the necessary background - Addresses cardiotoxicity related to current cancer therapeutic modalities - Discusses diagnostic and management approaches of patients with underlying cardiac risk factors as well as otherwise healthy cancer patients

In this issue of Heart Failure Clinics, guest editors Drs. Ragavendra R Baliga and George A. Mensah bring their considerable expertise to the topic of Translational Research in Cardio-Oncology. Top experts in the field cover key topics such as radiation-induced cardiac dysfunction; training and career development; cardiovascular imaging; CAR-T cell therapy and cardiovascular disease; and more. - Contains 12 relevant, practice-oriented topics including cardio-protection of high-risk individuals; myocardial metabolism; amyloidosis; arrhythmic complications associated with cancer therapies; and more. - Provides in-depth clinical reviews on translational research in cardio-oncology, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

Encyclopedia of Cardiovascular Research and Medicine, Four Volume Set offers researchers over 200 articles covering every aspect of cardiovascular research and medicine, including fully annotated figures, abundant color illustrations and links to supplementary datasets and references. With contributions from top experts in the field, this book is the most reputable and easily searchable resource of cardiovascular-focused basic and translational content for students, researchers, clinicians and teaching faculty across the biomedical and medical sciences. The panel of authors chosen from an international board of leading scholars renders the text trustworthy, contemporary and representative of the global scientific expertise in these domains. The book's thematic structuring of sections and in-depth breakdown of topics encourages user-friendly, easily searchable chapters. Cross-references to related articles and links to further reading and references will further guide readers to a full understanding of the topics under discussion. Readers will find an unparalleled, one-stop resource exploring all major aspects of cardiovascular research and medicine. Presents comprehensive coverage of every aspect of cardiovascular medicine and research Offers readers a broad, interdisciplinary overview of the concepts in cardiovascular research and medicine with applications across biomedical research Includes reputable, foundational content on genetics, cancer, immunology, cell biology and molecular biology Provides a multi-media enriched color-illustrated text with high quality images, graphs and tables.

Cardio-oncology is a medical subspecialty concerned with the diagnosis and treatment of cardiovascular disease (CVD) and organ failure mediated by micro- to macro-circulation defects in cancer patients and survivors. The risk of CVD in cancer survivors is eight times higher than the general population, and the relative risk of coronary artery disease and heart failure (HF) is 10 times and 15 times higher, respectively, compared to their siblings without cancer. It is important to note that cancer treatments including chemotherapy and radiation can lead to both short- (< 1 year) and long-term (> 5 years) cardiovascular complications. Previously, Dr. Edward T.H. Yeh initiated the MD Anderson Practice (MAP) project, and published 16 MAPs to provide the current best practice we considered at UT MD Anderson. As shown in these MAPs, one of the key issues of cardio-oncology practice and science is how we can allow cancer patients to receive maximum and uninterrupted treatments for cancer while protecting them from cancer therapy-mediated cardiovascular complications. Therefore, it is crucial to understand not only pathophysiology of CVD, but also mechanistic insights of how each cancer treatment can control cancer growth and metastasis. Without having the profound knowledge in the pathophysiological, clinical and epidemiologic aspects of cardiovascular complications of existing cancer therapy, it is impossible to establish the strong evidence-based strategies and approaches for both short- and long-term cardiovascular complications after cancer treatment. In addition, we believe that cardio-oncology science should not be restricted to deal with the side effects of each specific cancer drug, because many common cardiovascular phenotypes among the different cancer treatments are also observed. This Research Topic provides a comprehensive overview from both of the current research and practice, and a platform for obtaining the logical and up-to-date treatment and prevention of CVD in cancer patients and survivors.

Advanced Drug Delivery Systems in the Management of Cancer discusses recent developments in nanomedicine and nano-based drug delivery systems used in the treatment of cancers affecting the blood, lungs, brain, and kidneys. The research presented in this book includes international collaborations in the area of novel drug delivery for the treatment of cancer. Cancer therapy remains one of the greatest challenges in modern medicine, as successful treatment requires the elimination of malignant cells that are closely related to normal cells within the body. Advanced drug delivery systems are carriers for a wide range of pharmacotherapies used in many applications, including cancer treatment. The use of such carrier systems in cancer treatment is growing rapidly as they help overcome the limitations associated with conventional drug delivery systems. Some of the conventional limitations that these advanced drug delivery systems help overcome include nonspecific targeting, systemic toxicity, poor oral bioavailability, reduced efficacy, and low therapeutic index. This book begins with a brief introduction to cancer biology. This is followed by an overview of the current landscape in pharmacotherapy for the cancer management. The need for advanced drug delivery systems in oncology and cancer treatment is established, and the systems that can be used for several specific cancers are discussed. Several chapters of the book are devoted to discussing the latest technologies and advances in nanotechnology. These include practical solutions on how to design a more effective nanocarrier for the drugs used in cancer therapeutics. Each chapter is written with the goal of informing readers about the latest advancements in drug delivery system technologies while reinforcing understanding through various detailed tables, figures, and illustrations. Advanced Drug Delivery Systems in the Management of Cancer is a valuable resource for anyone working in the fields of cancer biology and drug delivery, whether in academia, research, or industry. The book will be especially useful for researchers in drug formulation and drug delivery as well as for biological and translational researchers working in the field of cancer. - Presents an overview of the recent perspectives and challenges within the management and diagnosis of cancer - Provides insights into how advanced drug delivery systems can effectively be used in the management of a wide range of cancers - Includes up-to-date information on diagnostic methods and treatment strategies using controlled drug delivery systems

This issue of Critical Care Clinics, Guest Edited by Dr. Stephen M. Pastores and Dr. Wendy R. Greene, focuses on Critical Care of the Cancer Patient (Pastores) and Geriatric Critical Care (Greene). Dr. Pastores' section of the issue is devoted to Critical Care of the Cancer Patient and includes the following topics: Triage and Prognostication of Cancer Patients Admitted to the ICU; ICU Organization and Interdisciplinary Care for Critically Ill Patients with Cancer; Critical Care of the Hematopoietic Stem Cell Transplant Recipient; Management of Drug Toxicities; Acute Kidney Injury in the Critically Ill Patient with Cancer; Infectious Disease Complications in Cancer Patients; and Palliative, Ethics, and End-of-Life Care Issues in the Cancer Patient. Dr. Green's section of the issue, devoted to Geriatric Critical Care, includes the following topics: The effect of aging physiology on critical care; The frailty syndrome: a critical issue in geriatric oncology; Detection of delirium in the intensive care unit: comparison of confusion assessment method for the intensive care unit with confusion assessment method ratings; Evidence-based geriatric nursing protocols for best practice; The effect of dementia in the critically ill geriatric patient; Nutritional assessment: a primary component of multidimensional geriatric assessment in the ICU; Rehabilitation concerns in the geriatric critically ill and injured; and Geriatric palliative care.

This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact.

This proposed text is designed to provide a useful and comprehensive resource and state-of-the-art overview to readers about vascular damage potentially induced by antineoplastic drugs. Thanks to more and more effective antineoplastic treatments the survival of cancer patients is enormously increasing, but at the same time it is increasing the burden of related cardiovascular complications that affect morbidity and mortality. On this basis a new branch of cardiology has been developed, that is Cardio-Oncology. The aim is to prevent cardiovascular complications related to cancer therapy and to facilitate and avoid interruption of antineoplastic drugs due to the occurrence of cardiovascular damage. An increasing attention has been given to cardiac damage, while, until today, vascular complications have been poorly evaluated. The aim of this book is to focus on vascular complications related to cancer treatment, to guide the clinician at facing, during his every day practice, cardiovascular toxicity in cancer and hematologic patients. The proposed sections of the book have been structured to review the molecular mechanisms underlying vascular damage induced by new and old treatments, to describe the various manifestations of vascular disease that may range from artery to venous disease (including coronary artery disease, peripheral arterial disease, venous thromboembolism and pulmonary hypertension), and to provide advice to monitor patients undergoing onco-hematologic treatments in order to prevent and eventually manage vascular damage.This book will address resident and fellow physicians, medical oncologists, cardiologists, general practitioners and all those who take care of these patients.All invited authors will be recognized experts in their field, and leading international researchers on these topics. The editor has worked with these expert colleagues on a variety of other projects. The authors will provide their manuscript according to current literature and clinical research studies. The book does not seek to duplicate or replace other current resources. Rather, it will create a comprehensive yet concise resource on this emerging topic that is not adequately covered by any current literature.